A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Primary Autonomic Failure - 0171 - Phase 3 Extension Study of TD-9855 for Treating snOH in Subjects with Primary Autonomic Failu

Theravance Biopharma Ireland Limited0 个研究点目标入组 120 人开始时间: 2019年11月25日最近更新: 2020年10月19日

适应症

试验速览

暂无简介。

•1. Completion of Study 0170 and, in the opinion of the Investigator, would benefit from long-term treatment with TD-9855.
•2. The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study procedures (including any changes occurring in the subject’s current therapeutic regimen).
•3. The subject must be willing to continue on treatment and must continue to meet all the inclusion criteria for the preceding study (Study 0170) except, a score of =4 in OHSA#1.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 71
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 49

•1. Subjects may not be enrolled in another clinical trial, with the exception of purely observational studies, which are allowed.
•2. Psychiatric, neurological, or behavioral disorders that may interfere with the ability of subjects to give informed consent, or interfere with the conduct of the study.
•3. Medical, laboratory, or surgical issues deemed by the Investigator to be clinically significant.
•4. Hypersensitivity to TD-9855 or the formulation excipients.

发起方